3-Dimensional QSAR and molecular docking studies of a series of indole analogues as inhibitors of human non-pancreatic secretory phospholipase A2

Kulwinder Singh, Monika ., Neelam Verma


Background:Design and development of new drugs is simplified and made more cost-effective because of the advances in the concepts of Quantitative Structure-Activity Relationship (QSAR) studies. A methodology of QSAR studies is one of the approaches to the rational drug design.

Methods:3-Dimensional QSAR studies were performed on a series of indole analogues as inhibitors of human non-pancreatic secretory phospholipaseA2 (PLA2) by using Scigress explorer software suite. Docking studies of these compounds were also performed to understand the interactions with amino acid residues of PLA2 protein.  

Results:The multiple linear regression analysis was used to correlate the physicochemical descriptors with the PLA2 inhibitory activity of 20 training set of compounds and the best QSAR model was developed. The best model was validated using leave-one-out method and found to be statistically significant, with coefficient of determination (r2) of 0.788. This model was further used to predict the PLA2 inhibitory activity of 12 test set of compounds. Docking analysis revealed that most of the compounds formed H-bond interactions with amino acid residues of PLA2 protein (PDB ID: 1DB4). Predicted pIC50 value of one of the test compounds was 7.454 and it showed H-bond interactions with Asp48, Cys44, His27, Gly29 and Gly31 residues.

Conclusion:The present study shall help in rational drug design and synthesis of new selective PLA2 inhibitors with predetermined affinity and activity and provides valuable information for the understanding of interactions between PLA2 and the novel indole analogue compounds.



QSAR, multiple linear regression, physicochemical descriptors, docking, PLA2, Scigress explorer, Molegro Virtual Docker

Full Text:



Hurt-Camejo E, Camejo G, Peilot H, Oorni K, Kovanen P. Phospholipase A2 in vascular disease. Circ Res. 2001;89:298-304.

Dennis EA. The growing phospholipase A2 superfamily of signal transduction enzymes. Trends Biochem Sci 1997;22:221-2.

Balsinde J, Balboa MA, Insel PA, Dennis EA. Regulation and inhibition of Phospholipase A2. Annu Rev Pharmacol Toxicol. 1999;39:175-89.

Nevalainen TJ. Serum phospholipases A2 in inflammatory diseases. Clin Chem. 1993;39:2453-9.

Vadas P, Pruzanski W. Role of secretory phospholipases A2 in the pathobiology of disease. Lab Invest. 1986;55:391-404.

Pruzanski W, Vadas P, Stefanski E, Urowitz MB. Phospholipase A2 activity in sera and synovial fluids in rheumatoid arthritis and osteoarthritis. Its possible role as a pro-inflammatory enzyme. J Rheumatol. 1985;12:211-6.

Rillema JA, Osmialowski EC, Linebaugh BE. Phospholipase A2 activity in 9,10-dimethyl-1,2-benzanthracene-induced mammary tumors of rats. Biochim Biophys Acta. 1980;617:150-5.

Fonteh AN, Bass DA, Marshall LA, Seeds M, Samet JM, Chilton FH. Evidence that secretory phospholipase A2 plays a role in arachidonic acid release and eicosanoid biosynthesis by mast cells. J Immunol. 1994;152:5438-46.

Vadas P, Pruzanski W. Induction of group II phospholipase A2 expression and pathogenesis of the sepsis syndrome. Circ Shock. 1993;39:160-7.

Nevalainen TJ, Gronroos JM, Kortesuo PT. Pancreatic and synovial type phospholipase A2 in serum from patients with severe acute pancreatitis. Gut. 1993;34:1133-6.

Minami T, Tojo H, Shinomura Y, Komatsubara T, Matsuzawa Y, Okamoto M. Elevation of phospholipase A2 protein in sera of patients with Crohn’s disease and ulcerative colitis. Am J Gastroenterol. 1993;88:1076-80.

Minami T, Tojo H, Shinomura Y, Matsuzawa Y, Okamoto M. Increased group II phospholipase A2 in colonic mucosa of patients with Crohn’s disease and ulcerative colitis. Gut. 1994;35:1593-8.

Testa B, Kier LB. The concept of molecular structure in structure-activity relationship studies and drug design. Med Res Rev. 1991;11:35-48.

Thakur A, Thakur M, Kakani N, Joshi A, Thakur A, Gupta A. Application of topological and physicochemical descriptors: QSAR study of phenylamino-acridine derivatives. ARKIVOC. 2004;14:36-43.

Mahajan S, Kamath V, Nayak S, Vaidya S. QSAR analysis of benzophenone derivatives as antimalarial agents. Indian J Pharm Sci. 2012;74:41-7.

Wolf M, Kubiyini H. Drug development research. In: James F. Kerwin Jr., eds. Burger’s Medicinal Chemistry and Drug Discovery. 5th ed. New York: Wiley Interscience Publishers; 1995: 116-117.

Roy PP, Paul S, Mitra I, Roy K. Two novel parameters for validation of predictive QSAR models. Molecules. 2009;14:1660-701.

Konovalov DA, Llewellyn LE, Heyden YV, Coomans DJ. Robust cross-validation of linear regression QSAR models. Chem Inf Model. 2008;48:2081-94.

Sudha KN, Shakira M, Prasanthi P, Sarika N, Kumar CN, Babu PA. Virtual screening for novel COX-2 inhibitors using the ZINC database. Bioinformation. 2008;2:325-9.

Thomsen R, Christensen MH. MolDock: a new technique for high-accuracy molecular docking. J Med Chem. 2006;49:3315-21.

Bolton E, Wang Y, Thiessen PA, Bryant SH. PubChem: integrated platform of small molecules and biological activities. In: Bolton E, Wang Y, Thiessen PA, Bryant SH, eds. Annual Reports in Computational Chemistry. 4th ed. UK, Oxford: Elsevier; 2008: 217-240.

Wang Y, Suzek T, Zhang J, Wang J, He S, Cheng T, et al. PubChem BioAssay: 2014 update. Nucleic Acids Res. 2014;42:D1075-82.

Selvaraj C, Tripathi SK, Reddy KK, Singh SK. Tool development for Prediction of pIC50 values from the IC50 values-A pIC50 value calculator. Curr Trends Biotechnol Pharm. 2011;5:1104-9.

ACD/ChemSketch Freeware 11.01, Advanced Chemistry Development, Inc., Toronto, Ontario, Canada, 2013. Available at: www.acdlabs.com.

ACD/3D Viewer, Advanced Chemistry Development, Inc., Toronto, Ontario, Canada, 2014. Available at: http://www.acdlabs.com/products/draw_nom/draw/chemsketch/3dviewer.php.

Halgren TA. Merck molecular force field: I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem. 1996;17:490-519.

Agrawal VK, Singh J, Mishra KC, Khadikar PV, Jaliwala YA. QSAR study on 5,6-dihydro-2-pyrones as HIV-1 protease inhibitors. ARKIVOC. 2006;2:162-77.

Eriksson L, Jaworska J, Worth AP, Cronin MTD, McDowell RM. Methods for reliability and uncertainty assessment and for applicability evaluations of classification and regression based QSARs. Environ Health Persp. 2003;111:1361-75.